低剖面主动脉腔内移植物13年系统综述与荟萃分析
该系统综述与荟萃分析纳入28项研究、1585例患者,评估低剖面主动脉腔内移植物(LPEGs)治疗腹主动脉瘤的安全性与疗效。总体技术成功率97.1%,30天死亡率0.9%,但随访期肢体闭塞率4.1%、晚期再干预率7.6%。结果支持在适合EVAR的患者尤其髂动脉解剖困难者中使用LPEGs,但肢体相关并发症仍需严格术后监测。
要点
- LPEGs总体技术成功率97.1%,30天死亡率仅0.9%。
- 随访期肢体闭塞率4.1%,晚期再干预率7.6%,为薄弱环节。
- 结果支持在髂动脉解剖困难患者中应用LPEGs。
核心结论
- LPEGs可用于适合EVAR的腹主动脉瘤患者,尤其髂动脉解剖困难者。
- 肢体相关并发症仍是部分器械的薄弱环节,需严格术后监测。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南检索至2025年4月的文献。
- 初检2744篇文献,最终纳入28项研究、1585例患者(88%为男性)。
主要发现
- 总体技术成功率97.1%(95%CI 95.4-98.2%;I2=68%),各器械为InCraft 94.5%、Zenith 97.7%、Ovation 98.7%、Minos 94.2%、Altura 98.8%。
- 30天死亡率为0.9%(95%CI 0.6%-1.3%;I2=0%,p=0.95)。
- 30天肢体闭塞率1.5%(95%CI 1.0-2.4%;I2=39%),随访期为4.1%(95%CI 2.9%-5.7%;I2=69%)。
- 30天再干预率2.7%(95%CI 1.8-4.0%;I2=57%),晚期再干预率7.6%(95%CI 5.3-10.8%;I2=89%)。
- 30天Ia型内漏发生率2.6%(95%CI 1.5-4.6%;I2=84%),晚期为1.5%(95%CI 1.0-2.3%;I2=37%)。
关键数值与推荐
- 总体30天辅助手术率为12.2%(95%CI 8.8-16.7%;I2=90%),各器械为InCraft 13.6%、Zenith 24.7%、Ovation 3.3%、Minos 15.4%、Altura 3.0%。
临床怎么用
- 对适合EVAR的腹主动脉瘤患者,可考虑使用LPEGs,尤其髂动脉解剖困难者。
- 术后需严格监测肢体相关并发症,警惕随访期肢体闭塞和再干预风险。
局限性
- 需进一步研究阐明并发症原因并评估器械长期耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this systematic review was to provide evidence-based data regarding the safety and efficacy of the low-profile endografts (LPEGs) for abdominal aortic aneurysms. METHODS: A systematic search of all the literature reported until April 2025 was performed according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. The main outcomes were technical success, mortality, limb occlusions, reintervention, type I endoleak and adjunctive procedures. RESULTS: A total of 2744 study titles were identified by the initial search strategy, of which 28 studies were considered eligible for inclusion in the present meta-analysis. A total of 1585 patients (88%, men) were identified among the eligible studies. The overall technical success rate was 97.1% (95% confidence interval [CI] 95.4-98.2%; I2=68%) (InCraft=94.5%; Zenith=97.7%; Ovation=98.7%; Minos=94.2%, Altura=98.8%) while the 30-day mortality rate was 0.9% (95% CI 0.6%-1.3%; I2=0%, p=0.95). The 30-day limb occlusion rate was 1.5% (95% CI 1.0-2.4%; I2=39%) (InCraft=1.9%; Zenith=1.5%; Ovation=1.2%; Minos=1.1%, Altura=1.2%) in the early period while during the follow-up, the limb occlusion rate was 4.1% (95% CI 2.9%-5.7%; I2=69%) (InCraft=5.1%; Zenith=6.0%; Ovation=2.3%; Minos=1.7%, Altura=1.8%). The 30-day reintervention rate was 2.7% (95% CI 1.8-4.0%; I2=57%) (Incraft=1.4%; Zenith=3.4%; Ovation=3.1%; Minos=1.7%; Altura=3.9%) while the pooled late reintervention rate was 7.6% (95% CI 5.3-10.8%; I2=89%) (InCraft=8.6%; Zenith=10.6%; Ovation=6.8%; Minos=3.4%, Altura=5.9%). The incidence of 30-day type Ia endoleak was 2.6% (95% CI 1.5-4.6%; I2=84%) (InCraft=5.9%; Zenith=1.2%; Ovation=2.0%; Minos=1.1%, Altura=1.2%) and 1.5% (95% CI 1.0-2.3%; I2=37%) (InCraft=1.0%; Zenith=1.4%; Ovation=1.6%; Minos=1.7%, Altura=1.2%) in the late period. The overall 30-day adjunctive procedures was 12.2% (95% CI 8.8-16.7%; I2=90%)(Incraft=13.6%; Zenith=24.7%; Ovation=3.3%; Minos=15.4%; Altura=3.0%). CONCLUSIONS: The present findings support the use of LPEGs in patients eligible for endovascular aortic aneurysm repair especially with hostile iliac anatomies. Limb-related complications remain the Achilles heel for certain devices, underscoring the need for strict postoperative surveillance. Further studies are warranted to investigate the underlying causes of these complications and to assess the long-term durability of these devices.Clinical ImpactThis study provides comprehensive data on the use of low-profile endografts (LPEGs) for the repair of abdominal aortic aneurysms (AAA). Despite significant advances in endograft technology, access-related challenges and limb complications remain among the most common adverse events associated with endovascular aneurysm repair (EVAR). The introduction of LPEGs was intended to broaden the applicability of EVAR to patients with complex anatomies, including narrow or tortuous access vessels and short or angulated aneurysm necks. The objective of this systematic review was to evaluate thirteen years of data on the safety and efficacy of LPEGs in AAA repair. Overall, the results support the use of LPEGs in appropriately selected patients, particularly those with hostile iliac anatomies. However, limb-related complications persist as the Achilles' heel of certain devices, highlighting the importance of vigilant postoperative surveillance. Further research is needed to elucidate the mechanisms behind these complications and to assess the long-term durability of these devices.
引用
- Karaolanis GI, Fanariotis G, Bekas N, et al. Thirteen Years Data of Low-Profile Aortic Endografts for Endovascular Aneurysm Repair: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2025. PMID: 41257336. doi:10.1177/15266028251388736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。